Health · Ai
OrsoBio
OrsoBio is a Palo Alto clinical-stage biopharmaceutical company developing first-in-class small-molecule therapies for severe metabolic disorders including obesity, type 2 diabetes, and MASH. Its lead approach uses liver-targeted mitochondrial protonophores that restore cellular energy homeostasis - biology inspired partly by how hibernating bears manage their metabolism ("orso" is Italian for bear). Incubated by Samsara BioCapital and led by former Gilead liver-disease leaders, the company has raised roughly $256M across four rounds and reported Phase 1b/2a data showing its lead candidate TLC-6740 added meaningful weight loss on top of the incretin drug tirzepatide.